Related Experiment Video

Updated: Nov 6, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis

Eduardo Mysler1, Ana Lizarraga1

  • 1Department of Rheumatology, OMI (Medical Research Organization), Uruguay, Buenos Aires, Argentina.

Rheumatology (Oxford, England)
|May 5, 2021
PubMed

Insights

Upadacitinib and filgotinib, selective JAK1 inhibitors, show rapid improvements in rheumatoid arthritis (RA) disease activity and function. This review critically examines phase III trials supporting their efficacy for RA treatment.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Trials

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • JAK inhibitors represent a novel therapeutic class for RA.
  • Upadacitinib and filgotinib are selective JAK1 inhibitors.

Purpose of the Study:

  • To critically review phase III clinical trial data for upadacitinib and filgotinib in RA.
  • To assess the therapeutic efficacy and safety of these JAK1 inhibitors.
  • To provide data supporting the approval and use of these drugs in RA management.

Main Methods:

  • Systematic review of published phase III randomized controlled trials.
  • Analysis of data from the SELECT (upadacitinib) and FINCH (filgotinib) programs.
  • Focus on efficacy outcomes, including disease activity, function, and patient-reported outcomes.

Main Results:

  • Both upadacitinib and filgotinib demonstrated rapid and significant improvements in RA disease activity and physical function.
  • Patient-reported outcomes showed marked benefits with both agents.
  • Safety profiles were evaluated across extensive trial programs.

Conclusions:

  • Upadacitinib and filgotinib are effective treatments for rheumatoid arthritis.
  • Phase III trial data support their therapeutic role in managing RA.
  • These JAK1 inhibitors offer rapid symptom control and functional improvement for RA patients.
Keywords:
JAK1 inhibitorsefficacyfilgotinibrheumatoid arthritisupadacitinb

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
83
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K